Key result
Updated 2022 PH guidelines revise haemodynamic definitions and classifications focusing on CHD-related subtypes.
Why the study?
Increasing understanding of normal pulmonary haemodynamics and evidence supporting early treatment have led to recent revisions in the haemodynamic definition of pulmonary hypertension.
This review provides an updated overview of the 2022 guideline definitions and classifications for pulmonary hypertension, highlighting its complex etiology in patients with congenital heart disease.
Alerts clinicians to 2022 PH definition revisions in CHD; leaves open prospective validation of updated classifications.
Pulmonary hypertension (PH) is a serious potential complication of some congenital heart diseases (CHDs). PH encompasses a range of diseases which may be idiopathic or inherited, or secondary to cardiac, respiratory, systemic or thromboembolic conditions, amongst others. Our increasing understanding of the normal ranges of pulmonary haemodynamics, as well as evidence supporting the benefits of early treatment, has resulted in a number of recent revisions to the haemodynamic definition of PH. In this Review Article, we report on the recent updates to haemodynamic definitions and classification of PH, as reflected in the 2022 Pulmonary Hypertension Guidelines and particularly focus on the CHD related sub-type of PH, where the aetiology is often multi-factorial.
No takes yet. Share an insight, caveat, or question.
Ratwatte et al. (2024) conducted a review in Pulmonary hypertension. Recent updates to the 2022 Pulmonary Hypertension Guidelines revised the haemodynamic definitions and classification of pulmonary hypertension, particularly for congenital heart disease-related subtypes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: